S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:ATRC

AtriCure - ATRC Stock Forecast, Price & News

$50.73
-0.07 (-0.14%)
(As of 08/11/2022 04:24 PM ET)
Add
Compare
Today's Range
$50.53
$52.47
50-Day Range
$35.10
$51.44
52-Week Range
$32.83
$89.18
Volume
114,878 shs
Average Volume
266,416 shs
Market Capitalization
$2.36 billion
P/E Ratio
43.73
Dividend Yield
N/A
Price Target
$75.86

AtriCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.5% Upside
$75.86 Price Target
Short Interest
Healthy
3.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of AtriCure in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$136,736 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.09) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

251st out of 1,112 stocks

Surgical & Medical Instruments Industry

20th out of 113 stocks

ATRC stock logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure Price Performance

ATRC Stock traded up $1.88 during midday trading on Wednesday, reaching $50.80. The company had a trading volume of 155,224 shares, compared to its average volume of 267,413. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of 43.79 and a beta of 1.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.66 and a quick ratio of 2.93. AtriCure has a 1-year low of $32.83 and a 1-year high of $89.18. The stock has a 50 day moving average price of $43.09 and a 200-day moving average price of $52.97.

AtriCure (NASDAQ:ATRC - Get Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Equities research analysts expect that AtriCure will post -1.09 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATRC. Stifel Nicolaus reduced their price objective on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. Needham & Company LLC increased their price objective on AtriCure from $55.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, August 3rd. BTIG Research reduced their target price on shares of AtriCure from $94.00 to $75.00 and set a "buy" rating for the company in a research report on Friday, June 24th. Piper Sandler decreased their price target on shares of AtriCure from $90.00 to $55.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 3rd. Finally, StockNews.com cut shares of AtriCure from a "hold" rating to a "sell" rating in a research note on Sunday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.86.

Insider Transactions at AtriCure

In other AtriCure news, insider Tonya Austin sold 3,203 shares of AtriCure stock in a transaction dated Friday, May 13th. The stock was sold at an average price of $42.69, for a total value of $136,736.07. Following the transaction, the insider now owns 17,621 shares in the company, valued at $752,240.49. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.80% of the stock is owned by insiders.

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Cut to "Sell" at StockNews.com
AtriCure (NASDAQ:ATRC) Lowered to Sell at StockNews.com
AtriCure (NASDAQ:ATRC) PT Lowered to $55.00 at Piper Sandler
AtriCure (NASDAQ:ATRC) PT Raised to $65.00
Is AtriCure (NASDAQ:ATRC) Using Too Much Debt?
AtriCure (ATRC) Set to Announce Quarterly Earnings on Tuesday
AtriCure (NASDAQ:ATRC) Cut to Sell at StockNews.com
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings
8/02/2022
Today
8/11/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
875
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$75.86
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+49.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$50.20 million
Pretax Margin
17.68%

Debt

Sales & Book Value

Annual Sales
$274.33 million
Cash Flow
$0.99 per share
Book Value
$9.84 per share

Miscellaneous

Free Float
45,125,000
Market Cap
$2.36 billion
Optionable
Optionable
Beta
1.20

Social Links















ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price forecast for 2022?

5 equities research analysts have issued twelve-month price targets for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $110.00. On average, they expect the company's stock price to reach $75.86 in the next year. This suggests a possible upside of 48.2% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2022?

AtriCure's stock was trading at $69.53 at the beginning of the year. Since then, ATRC shares have decreased by 26.4% and is now trading at $51.19.
View the best growth stocks for 2022 here
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Tuesday, August, 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.02. AtriCure had a negative trailing twelve-month return on equity of 11.47% and a net margin of 17.62%. During the same quarter in the prior year, the business posted ($0.30) earnings per share.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of -$1.12--$1.07 for the period, compared to the consensus earnings per share estimate of -$1.10. The company issued revenue guidance of $323.00 million-$333.00 million, compared to the consensus revenue estimate of $324.43 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Loomis Sayles & Co. L P (1.99%), TimesSquare Capital Management LLC (1.95%), Fiera Capital Corp (1.53%), Eagle Asset Management Inc. (1.41%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.01%) and Emerald Advisers LLC (0.93%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $51.19.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.38 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.16 on an earnings per share basis.

How many employees does AtriCure have?

The company employs 875 workers across the globe.

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART.
Read More

When was AtriCure founded?

AtriCure was founded in 2000.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.